Launch of FundaMental Pharma

Sunday 27 November 2022
Country

Germany

A new German neuroscience company was formally launched in Heidelberg on 17 November with plans to develop small molecule drugs for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis and Huntington’s disease. FundaMental Pharma GmbH has received €10 million in seed financing from a consortium led by BioGeneration Ventures and Thuja Capital of the Netherlands and High-Tech Gründerfonds in Germany.